ArticleBMC infectious diseases2025
Elevated CD4⁺/CD8⁺ ratio and D-dimer as diagnostic biomarkers for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis versus infectious mononucleosis in children: a retrospective case-control study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Development of a machine learning-based assistive diagnostic model for Epstein‑Barr virus‑associated hemophagocytic lymphohistiocytosis in pediatric patients.Translational pediatrics · 2026Article
- Early Differential Diagnosis of Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome in Children: A Clinical Prediction Model Based on 106 Patients.Pathogens (Basel, Switzerland) · 2026Article
- Development and external validation of a machine learning prediction model for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children using routine blood parameters: a retrospective cohort study.BMC infectious diseases · 2026Article
- Role of plasma D-dimer levels as diagnostic and prognostic marker in neonatal sepsis: An insightful support.World journal of clinical pediatrics · 2026Article
- Early Risk Factors and Clinical Characteristics of Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Retrospective Study.Journal of inflammation research · 2026Article
- EBV-DNA viral load and lymphocyte subsets correlation in pediatric infectious mononucleosis with hepatic injury a retrospective cohort study.Frontiers in pediatrics · 2026Article
- The clinical utility of combining D-dimer with the C-reactive protein/albumin ratio for assessing treatment response in pediatric infectious mononucleosis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify potential diagnostic biomarkers distinguishing Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) from infectious mononucleosis (EBV-IM) in pediatric patients using a retrospective case-control design.
methodsThis study enrolled a total of 160 pediatric patients, including 132 with Epstein-Barr virus-associated infectious mononucleosis (EBV-IM) and 28 with EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH). Serum levels of CD4⁺ T cells, CD8⁺ T cells, and D-dimer were quantified by flow cytometry and immunoturbidimetry, respectively. The CD4⁺/CD8⁺ ratio was calculated from absolute counts. These parameters, along with clinical and laboratory features, were compared between the EBV-IM and EBV-HLH groups. Binary logistic regression was used to analyze the risk factors for the progression of EBV infection to EBV-HLH. The clinical value of CD4⁺/CD8⁺ ratio and D-dimer levels in diagnosing EBV-HLH was assessed using receiver operating characteristic (ROC) curve analysis.
resultsThe average age of the EBV-HLH group was significantly lower than that of the IM group (p < 0.05). The EBV-HLH group had significantly higher levels of NLR(Neutrophil to Lymphocyte Ratio), PLR(Platelet to Lymphocyte Ratio), D-dimer, EBV-DNA, disease duration, CD4⁺/CD8⁺ ratio, and AST/ALT compared to the IM group (p < 0.05).Binary logistic regression analysis indicated that a higher CD4⁺/CD8⁺ ratio (OR = 17.60, 95% CI: 1.89-163.64; p < 0.05) and elevated D-dimer levels (OR = 1.31 per 1 mg/L increase, 95% CI: 1.08-1.59; p < 0.05) were significantly associated with EBV-HLH. Building upon the identified associations, we evaluated the diagnostic performance of these biomarkers. ROC curve analysis demonstrated that CD4⁺/CD8⁺ ratio > 0.455 (Youden index = 0.638, sensitivity = 92.4%, specificity = 71.4%) and D-dimer > 1.675 mg/L (Youden index = 0.683, sensitivity = 82.6%, specificity = 85.7%) optimally discriminated EBV-HLH from EBV-IM. The combined model significantly enhanced diagnostic accuracy (Youden index = 0.811), with AUC values of 0.837 (95%CI: 0.76-0.91), 0.869 (95%CI: 0.80-0.94), and 0.962 (95%CI: 0.935-0.989) for CD4⁺/CD8⁺ ratio, D-dimer, and their combination, respectively.
conclusionElevated CD4⁺/CD8⁺ ratio and D-dimer serve as potential diagnostic biomarkers for pediatric EBV-HLH. Their combined detection enhances differentiation from EBV-IM, though validation through prospective studies is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.